Introduction {#section1-1177390117727533}
============

Amphetamines and related compounds which include amphetamine (AMP), methamphetamine (MA), 4-methylamphetamine (4-MA), 3,4-methylenedioxyamphetamine (MDA), 3,4-methylenedioxymethamphetamine (MDMA), 3,4-methylenedioxy-*N*-ethylamphetamine (MDEA), cathinone (CAT), and ephedrine (EPH) are widely acknowledged as the drugs of abuse in the market.^[@bibr1-1177390117727533][@bibr2-1177390117727533]--[@bibr3-1177390117727533]^ More recently, a new synthetic cathinones such as methcathinone (MC) and mephedrone (MEP) are emerging in the market as a bath salt.^[@bibr4-1177390117727533]^ Their stimulant, euphoric, anorectic effects appear to be the main reason for its popularity.^[@bibr5-1177390117727533],[@bibr6-1177390117727533]^

Amphetamines and cathinones are weak bases with relatively low molecular weights. It can diffuse to tissues and biological fluids which have pH lower than blood. In addition to urine and blood, amphetamines and cathinones were detected in alternative biological matrices such as sweat, oral fluid, and hair.^[@bibr7-1177390117727533],[@bibr8-1177390117727533]^

The use of oral fluid for drug testing has many advantages over conventional matrices, it is safe to collect and can offer a quick and noninvasive specimen and condense the potential for adulteration.^[@bibr9-1177390117727533],[@bibr10-1177390117727533]^ Indeed, in many cases, the concentration of drugs in oral fluid represents the physiologically active fraction.^[@bibr11-1177390117727533],[@bibr12-1177390117727533]^ The basic drugs such as the cocaine, amphetamines, and some opioids have similar or higher concentrations in oral fluid than those in plasma; therefore, the use of oral fluid as alternative specimens to blood or urine for testing drugs of abuse has become a great importance in clinical and forensic toxicology.^[@bibr9-1177390117727533],[@bibr13-1177390117727533]^

Practically, gas chromatography-mass spectrometry (GC-MS) analysis of amphetamines and cathinones without derivatization do not confer satisfactory chromatographic behavior. Acylation of the amino or alkylamino groups of amphetamines or cathinones is required to improve the chromatographic shape. Fluorinated anhydrides such as heptafluorobutyric anhydride (HFBA), pentafluoropropionic anhydride (PFPA), and trifluoroacetic anhydride (TFAA) are the most popular derivatizing agents for the derivatization of amphetamines and cathinones prior to GC-MS analysis^[@bibr14-1177390117727533][@bibr15-1177390117727533][@bibr16-1177390117727533][@bibr17-1177390117727533][@bibr18-1177390117727533][@bibr19-1177390117727533][@bibr20-1177390117727533][@bibr21-1177390117727533][@bibr22-1177390117727533][@bibr23-1177390117727533][@bibr24-1177390117727533][@bibr25-1177390117727533][@bibr26-1177390117727533][@bibr27-1177390117727533][@bibr28-1177390117727533][@bibr29-1177390117727533][@bibr30-1177390117727533][@bibr31-1177390117727533][@bibr32-1177390117727533]--[@bibr33-1177390117727533]^ but it is not clear which would be the most effective one.

In this work, 3 acylation reagents, HFBA, PFPA, and TFAA, are evaluated for derivatization of AMP, MA, 4-MA, MDA, MDMA, MDEA, CAT, MC, MEP, and EPH after extraction from the oral fluid.

Materials and Methods {#section2-1177390117727533}
=====================

Chemicals, reagents, and materials {#section3-1177390117727533}
----------------------------------

Stock standards of [d]{.smallcaps}-AMP.HCl, [d]{.smallcaps},[l]{.smallcaps}-CAT.HCl, [d]{.smallcaps},[l]{.smallcaps}-4-MA.HCl, [d]{.smallcaps},[l]{.smallcaps}-MA.HCl, [d]{.smallcaps},[l]{.smallcaps}-MDA.HCl, [d]{.smallcaps},[l]{.smallcaps}-MDMA.HCl, [d]{.smallcaps},[l]{.smallcaps}-MDEA.HCl, [d]{.smallcaps},[l]{.smallcaps}-AMP-D~5~.HCl, [d]{.smallcaps},[l]{.smallcaps}-MA-D~5~.HCl, [d]{.smallcaps},[l]{.smallcaps}-MDA-D~5~.HCl, [d]{.smallcaps},[l]{.smallcaps}-MDMA-D~5~.HCl, and [d]{.smallcaps},[l]{.smallcaps}-MDEA-D~5~.HCl at concentrations of 1.0 mg/mL free base in methanol were obtained from Lipomed AG (Arlesheim, Switzerland). Mephedrone HCl, S(−)-MC HCl and 1S,2R(+)-EPH HCl stock standards at a concentration of 1.0 mg/mL free base in methanol were purchased from Cerilliant (Round Rock, TX, USA). The reagents HFBA, PFPA, and TFAA were supplied by United Chemical (UCT, Bristol, PA, USA). Methanol (high-performance liquid chromatography grade, 99.9%), ethyl acetate (99.9%), and sodium hydroxide (≥99.0%) were purchased from Fisher Scientific (Hampton, NH, USA). The GC vials (1.5 mL) and inserts (150 µL) were obtained from Agilent (Santa Clara, CA, USA).

GC-MS conditions {#section4-1177390117727533}
----------------

An Agilent GC-MS-7890B with an Agilent autosampler was used for specimen analysis. The GC was equipped with Agilent HP-5MS (5%-phenyl-methylpolysiloxane) column capillary column (30 m × 250 µm × 0.25 µm film thickness). Helium was used as the carrier gas at a flow rate of 1 mL/min. The injection volume was 2.0 µL and injections were made in splitless mode. The injector and interface temperature were maintained at 280°C. The column temperature program was initialized at 80°C and held for 2 minutes, increased to 150°C at a ramp rate of 8°C/min, and then to 280°C with a ramp rate of 30°C/min. Solvent delay time was 6 minutes, giving a total run time of 15.0 minutes. Electron impact ionization mode was used for ionization. The ionizing energy was 70 eV. Qualitative analysis was conducted in the full scan mode (*m/z* range: 50-500), and quantification was in the in selected ion monitoring (SIM) mode. The deuterated analogues of amphetamines were used as internal standard (IS) for the target compounds, whereas AMP-D~5~ for AMP, CAT, and 4-MA; MA-D~5~ for MA, EPH, MC, and MEP; MDA-D~5~ for MDA; and MDMA-D~5~ for MDMA and MDMA-D~5~ for MDEA. Data analysis was performed using the Agilent GC-MS software (MassHunter).

Standards solutions {#section5-1177390117727533}
-------------------

A mixture of working solution of amphetamines and cathinones at a concentration of 100 µg/mL was prepared by diluting (1:10) of the stock standards with methanol in a volumetric flask. Further working solutions of 10.0, 1.0, and 0.1 μg/mL were obtained and used for the preparation of calibrators. A mixture of IS at a concentration of 5.0 µg/mL for AMP-D~5~, MA-D~5~, MDA-D~5~, MDMA-D~5~, and MDEA-D~5~ was prepared by pipetting 50 µL of each compound (100 µg/mL) in 10-mL volumetric flask and made up to 10 mL with methanol.

Spiked samples {#section6-1177390117727533}
--------------

For the linearity study, calibration curves at the concentrations of 5, 10, 25, 50, 100, 500, and 1000 ng/mL were prepared in triplicate by fortifying pool of blank oral fluid with appropriate volumes of the mix working solutions.

For the limit of quantification (LOQ) study, a pool of blank oral fluid was fortified with the target compounds at a concentration of 100 ng/mL and then a series of fortified oral fluid (n = 3) at concentrations of 1, 2.5, 5, and 10 ng/mL were prepared.

Sample preparation {#section7-1177390117727533}
------------------

To 0.5 mL of oral fluid specimens in 5-mL polypropylene tubes, 50 µL of IS (5.0 µg/mL), 0.5 mL of 0.1 N of NaOH (pH 14), and 3.0 mL of ethyl acetate were added. The tubes were vortex mixed for 3 minutes and centrifuged (3000 rpm) for 5 minutes. The ethyl acetate layer was transferred to 5-mL glass tubes containing 1% HCl in methanol, gently vortexed, and evaporated to dryness using a stream of nitrogen. To the residue, 50 µL of ethyl acetate and 50 µL of HFBA, PFPA, or TFAA were added and heated for 30 minutes at 70°C. Samples were evaporated to dryness under a stream of nitrogen and reconstituted with 50 µL of ethyl acetate.

Measurements procedures {#section8-1177390117727533}
-----------------------

Calibration graphs were established by plotting the peak area ratio of the analyte to the IS versus analyte concentration. The linearity of the method was investigated by evaluation of the correlation coefficient (*r*^2^) for each calibration graph and the accuracy (bias) for each calibrator.^[@bibr34-1177390117727533]^ The acceptable value for bias was ±15% and ±20% for LOQ.

Sensitivity for each method was assessed by determining the limit of detection (LOD) and LOQ for all analytes.^[@bibr34-1177390117727533]^ The LOD was defined as the lowest concentration for which the analyte ion signal-to-noise (S/N) ratio was ≥3 (determined by peak height). The LOQ was defined as the lowest concentration for which the analyte ion S/N ratio was ≥10.

Method specificity was evaluated by analysis of 6 different blanks (no analyte or IS) and negative (IS added) oral fluid specimens.^[@bibr34-1177390117727533]^ Co-eluting peaks that might interfere with detection of analytes or IS was examined.

Results and Discussion {#section9-1177390117727533}
======================

Confirmation of unknown amphetamines and cathinones using GC-MS depends on retention time and mass spectra. When SIM is used in place of full scan, at least 3 characteristic ions should be selected and ion ratios must be evaluated.^[@bibr35-1177390117727533]^ In this study, SIM was applied to detect and quantify amphetamines and cathinones using 3 different derivatization methods.

The mass spectra of HFB, PFP, and TFA derivatives of the target amphetamines and cathinones are shown in [Figures 1](#fig1-1177390117727533){ref-type="fig"} to [3](#fig3-1177390117727533){ref-type="fig"}. The ions with a higher *m*/*z* ratio were used as a quantifier and qualifier ions. Based on S/N, the most intense ion was used as a quantifier and 2 characteristic ions were used as a qualifier. The quantifier and qualifier ions for derivatized amphetamines and cathinones by HFBA, PFPA, and TFAA are presented in [Table 1](#table1-1177390117727533){ref-type="table"}. The principal fragmentation occurs by dissociation of the α and β-carbon bonds, as presented in the figure. The fragment ions at *m*/*z* 344, 294, 244 for HFB-, PFP-, and TFA-EPH, respectively, are characteristic ions to distinguish between EPH and MA, whereas the retention times for both are close to each other after PFP and TFA derivatization.

![Mass spectra for HFB derivatives of the target amphetamines and cathinones. AMP indicates amphetamine; CAT, cathinone; EPH, ephedrine; 4-MA, 4-methylamphetamine; MA, methamphetamine; MC, methcathinone; MDA, 3,4-methylenedioxyamphetamine; MDEA, 3,4-methylenedioxy-*N*-ethylamphetamine; MDMA, 3,4-methylenedioxymethamphetamine; MEP, mephedrone.](10.1177_1177390117727533-fig1){#fig1-1177390117727533}

![Mass spectra for PFP derivatives of the target amphetamines and cathinones. AMP indicates amphetamine; CAT, cathinone; EPH, ephedrine; 4-MA, 4-methylamphetamine; MA, methamphetamine; MC, methcathinone; MDA, 3,4-methylenedioxyamphetamine; MDEA, 3,4-methylenedioxy-*N*-ethylamphetamine; MDMA, 3,4-methylenedioxymethamphetamine; MEP, mephedrone.](10.1177_1177390117727533-fig2){#fig2-1177390117727533}

![Mass spectra for TFA derivatives of the target amphetamines and cathinones. AMP indicates amphetamine; CAT, cathinone; EPH, ephedrine; 4-MA, 4-methylamphetamine; MA, methamphetamine; MC, methcathinone; MDA, 3,4-methylenedioxyamphetamine; MDEA, 3,4-methylenedioxy-*N*-ethylamphetamine; MDMA, 3,4-methylenedioxymethamphetamine; MEP, mephedrone.](10.1177_1177390117727533-fig3){#fig3-1177390117727533}

###### 

Ions monitored for gas chromatography-mass spectrometry analysis for HFA, PFP, and TFA derivatives of the target amphetamines and cathinones.

![](10.1177_1177390117727533-table1)

  Name        HFBA   PFPA       TFAA                    
  ----------- ------ ---------- ------ ---------- ----- ----------
  AMP         240    91, 118    190    91, 118    140   91, 118
  4-MA        132    105, 240   132    105, 190   132   105, 140
  MA          254    118, 210   204    160, 118   154   110, 118
  MDA         375    135, 162   162    135, 325   275   135, 162
  MDMA        254    162, 210   204    162, 339   154   110, 162
  MDEA        268    240, 403   218    190, 353   168   140, 303
  CAT         105    77, 240    105    77, 190    105   77, 140
  MC          254    105, 210   204    105, 160   154   105, 110
  MEP         119    210, 254   119    160, 204   119   91, 154
  EPH         254    210, 344   204    160, 294   154   110, 244
  AMP-D~5~    244    122, 123   194    122, 123   144   92, 123
  MA-D~5~     258    120, 213   208    119, 163   158   113, 120
  MDA-D~5~    380    136, 167   167    136, 330   280   136, 167
  MDMA-D~5~   258    164, 213   208    164, 344   158   164, 113
  MDEA-D~5~   273    241, 408   223    191, 358   173   141, 308

Abbreviations: AMP, amphetamine; CAT, cathinone; EPH, ephedrine; HFBA, heptafluorobutyric anhydride; 4-MA, 4-methylamphetamine; MA, methamphetamine; MC, methcathinone; MDA, 3,4-methylenedioxyamphetamine; MDEA, 3,4-methylenedioxy-*N*-ethylamphetamine; MDMA, 3,4-methylenedioxymethamphetamine; MEP, mephedrone; PFPA, pentafluoropropionic anhydride; TFAA, trifluoroacetic anhydride.

The calibration graphs for each analyte showed good linearity over the dynamic range of 5 to 2000 or 10 to 2000 ng/mL within 3 regression curves. Linear correlation coefficients (*r*^2^) were calculated from the triplicate analyses at 6 and 7 concentrations. All *r*^2^ values were greater than 0.97. The best *r*^2^ values were obtained with PFPA (0.99). Linear ranges, accuracy, and precision (n = 3) for each analyte are presented in [Tables 2](#table2-1177390117727533){ref-type="table"} to [4](#table4-1177390117727533){ref-type="table"}. Accuracy expressed as a bias and precision expressed as a relative standard deviation were evaluated at each calibration level. The acceptable value for bias was ±15% and ±20% for LOQ. As depicted in the tables, accuracy and precision were within the acceptable limits.

###### 

Accuracy and precision data and linearity range (n = 3) for HFA derivatives of the target amphetamines and cathinones.

![](10.1177_1177390117727533-table2)

  Analyte      Concentration, ng/mL                                                                       
  ------------ ---------------------- ------------ ------------ ------------ ------------- -------------- ----------------
  AMP                                                                                                     
   Mean ± SD   ---                    10.5 ± 0.9   23.6 ± 1.2   50.2 ± 3.0   98.7 ± 10.4   510.3 ± 45.7   1017.4 ± 38.3
   %RSD                               8.9          5.0          6.1          10.6          9.0            3.8
   %Bias                              4.7          −5.7         0.3          −1.3          2.1            1.7
  4-MA                                                                                                    
   Mean ± SD   5.0 ± 0.3              10.6 ± 0.7   24.5 ± 0.9   52.2 ± 3.6   96.8 ± 6.5    499.3 ± 15.0   1047.7 ± 51.9
   %RSD        5.9                    6.4          3.5          6.9          6.7           3.0            5.0
   %Bias       0.3                    5.8          −1.9         4.5          −3.2          −0.1           4.8
  MA                                                                                                      
   Mean ± SD   4.9 ± 0.5              9.5 ± 0.9    24.9 ± 2.0   51.9 ± 5.6   99.2 ± 10.9   522.1 ± 62.6   1064.4 ± 67.5
   %RSD        10.5                   9.4          8.0          10.7         11.0          12.0           6.3
   %Bias       −2.5                   −5.3         −0.4         3.9          −0.8          4.4            6.4
  MDA                                                                                                     
   Mean ± SD   ---                    9.9 ± 1.0    25.9 ± 1.3   52.8 ± 4.0   90.8 ± 2.6    491.8 ± 58.7   1095.3 ± 25.0
   %RSD                               10.1         5.0          7.6          2.8           11.9           2.3
   %Bias                              −0.6         3.7          5.6          −9.2          −1.6           9.5
  MDMA                                                                                                    
   Mean ± SD   4.7 ± 0.5              10.4 ± 0.8   25.3 ± 0.9   53.3 ± 2.2   91.0 ± 3.0    517.1 ± 64.6   1093.8 ± 21.5
   %RSD        11.1                   7.8          3.7          4.2          3.3           12.5           2.0
   %Bias       −5.8                   4.1          1.2          6.6          −9.1          3.4            9.4
  MDEA                                                                                                    
   Mean ± SD   5.1 ± 0.2              11.0 ± 0.1   24.6 ± 0.7   50.7 ± 3.6   105.2 ± 7.7   465.2 ± 47.8   1101.1 ± 131.7
   %RSD        3.1                    0.6          2.9          7.0          7.3           10.3           12.0
   %Bias       1.8                    10.4         −1.7         1.4          5.2           −7.0           10.1
  EPH                                                                                                     
   Mean ± SD   5.1 ± 0.1              10.1 ± 0.9   24.9 ± 3.0   47.9 ± 1.4   93.9 ± 7.0    498.2 ± 29.5   1166.0 ± 42.4
   %RSD        1.8                    9.0          12.0         2.9          7.5           5.9            3.6
   %Bias       1.1                    0.9          −0.5         −4.2         −6.1          −0.4           16.6
  CAT                                                                                                     
   Mean ± SD   5.3 ± 0.5              9.0 ± 0.1    24.8 ± 1.0   47.4 ± 2.2   107.5 ± 4.5   545.4 ± 12.0   1083.2 ± 56.4
   %RSD        10.4                   1.7          3.9          4.7          4.2           2.2            5.2
   %Bias       5.1                    −10.2        −0.7         −5.1         7.5           9.1            8.3
  MC                                                                                                      
   Mean ± SD   4.6 ± 0.4              10.0 ± 0.2   23.7 ± 1.8   51.8 ± 2.1   94.3 ± 8.8    488.2 ± 48.3   1077.0 ± 48.3
   %RSD        8.3                    2.2          7.7          4.1          9.4           9.9            4.5
   %Bias       −7.2                   −0.4         −5.2         3.5          −5.7          −2.4           7.7
  MEP                                                                                                     
   Mean ± SD   5.6 ± 0.6              11.0 ± 0.1   25.9 ± 1.4   47.6 ± 1.9   106.4 ± 8.0   500.5 ± 16.3   1041.3 ± 80.9
   %RSD        11.0                   0.6          5.6          4.0          7.5           3.3            7.8
   %Bias       11.0                   10.1         3.4          −4.9         6.4           0.1            4.1

Abbreviations: AMP, amphetamine; CAT, cathinone; EPH, ephedrine; 4-MA, 4-methylamphetamine; MA, methamphetamine; MC, methcathinone; MDA, 3,4-methylenedioxyamphetamine; MDEA, 3,4-methylenedioxy-*N*-ethylamphetamine; MDMA, 3,4-methylenedioxymethamphetamine; MEP, mephedrone; RSD, relative standard deviation.

###### 

Accuracy and precision data and linearity range (n = 3) for PFP derivatives of the target amphetamines and cathinones.

![](10.1177_1177390117727533-table3)

  Analyte      Concentration, ng/mL                                                                       
  ------------ ---------------------- ------------ ------------ ------------ ------------- -------------- ---------------
  AMP                                                                                                     
   Mean ± SD   4.7 ± 0.5              10.4 ± 0.5   26.6 ± 1.6   47.1 ± 0.7   85.9 ± 0.3    525.5 ± 78.3   1000.9 ± 47.9
   %RSD        9.9                    5.1          5.8          1.6          0.3           14.9           4.8
   %Bias       −6.7                   4.3          6.5          −5.8         −14.1         5.1            0.1
  4-MA                                                                                                    
   Mean ± SD   5.1 ± 0.2              9.5 ± 0.3    24.6 ± 0.6   46.5 ± 0.1   105.6 ± 6.4   466.9 ± 32.9   956.7 ± 76.5
   %RSD        3.9                    3.4          2.4          0.2          6.1           7.0            8.0
   %Bias       1.2                    −5.2         −1.7         −7.1         5.6           −6.6           −4.3
  MA                                                                                                      
   Mean ± SD   5.4 ± 0.2              10.6 ± 0.7   25.0 ± 1.5   52.7 ± 3.5   88.7 ± 0.5    493.0 ± 42.1   1033.2 ± 39.3
   %RSD        3.2                    6.1          6.0          6.6          0.6           8.5            3.8
   %Bias       8.4                    6.4          0.2          5.3          −11.3         −1.4           3.3
  MDA                                                                                                     
   Mean ± SD   5.2 ± 0.1              9.4 ± 0.7    26.0 ± 2.7   54.1 ± 2.8   89.1 ± 1.4    474.5 ± 0.7    1134.6 ± 13.3
   %RSD        1.9                    7.2          10.3         5.1          1.6           0.1            1.2
   %Bias       4.0                    −6.4         4.0          8.3          −10.9         −5.1           13.5
  MDMA                                                                                                    
   Mean ± SD   5.4 ± 0.4              9.3 ± 0.9    25.1 ± 1.4   47.2 ± 3.8   90.1 ± 1.7    461.5 ± 11.3   1064.8 ± 7.7
   %RSD        7.4                    9.2          5.7          8.1          1.8           2.5            0.7
   %Bias       7.7                    −7.0         0.4          −5.6         −9.9          −7.7           6.5
  MDEA                                                                                                    
   Mean ± SD   4.7 ± 0.1              10.0 ± 0.3   26.6 ± 0.7   52.0 ± 2.5   108.1 ± 3.7   462.4 ± 12.1   1070.1 ± 45.7
   %RSD        1.9                    3.3          2.7          4.8          3.4           2.6            4.3
   %Bias       −5.3                   −0.5         6.4          4.0          8.1           −7.5           7.0
  EPH                                                                                                     
   Mean ± SD   5.3 ± 0.1              9.0 ± 0.2    27.4 ± 0.9   54.1 ± 4.4   92.5 ± 4.7    470.4 ± 46.0   1060.6 ± 71.1
   %RSD        1.6                    2.1          3.4          8.2          5.1           9.8            6.7
   %Bias       6.8                    −10.3        9.5          8.3          −7.5          −5.9           6.1
  CAT                                                                                                     
   Mean ± SD   4.8 ± 0.1              11.0 ± 0.1   26.2 ± 1.3   49.4 ± 1.3   106.7 ± 8.0   473.4 ± 19.2   1062.0 ± 35.4
   %RSD        2.0                    1.4          4.9          2.6          7.5           4.1            3.3
   %Bias       −3.4                   9.9          4.7          −1.2         6.7           −5.3           6.2
  MC                                                                                                      
   Mean ± SD   5.0 ± 0.1              9.0 ± 0.1    26.2 ± 0.5   50.6 ± 5.0   103.9 ± 8.2   517.2 ± 22.4   956.5 ± 43.2
   %RSD        2.0                    0.8          1.8          9.9          7.9           4.3            4.5
   %Bias       −0.8                   −9.6         4.9          1.1          3.9           3.4            −4.3
  MEP                                                                                                     
   Mean ± SD   5.0 ± 0.2              8.9 ± 0.1    24.6 ± 0.7   50.3 ± 1.6   105.2 ± 6.1   473.1 ± 34.0   1101.5 ± 14.8
   %RSD        4.3                    1.0          2.8          3.1          5.8           7.2            1.3
   %Bias       −1.0                   −10.7        −1.5         0.6          5.2           −5.4           10.1

Abbreviations: AMP, amphetamine; CAT, cathinone; EPH, ephedrine; 4-MA, 4-methylamphetamine; MA, methamphetamine; MC, methcathinone; MDA, 3,4-methylenedioxyamphetamine; MDEA, 3,4-methylenedioxy-*N*-ethylamphetamine; MDMA, 3,4-methylenedioxymethamphetamine; MEP, mephedrone; RSD, relative standard deviation.

###### 

Accuracy and precision data and linearity range (n = 3) for TFA derivatives of the target amphetamines and cathinones.

![](10.1177_1177390117727533-table4)

  Analyte      Concentration, ng/mL                                                                       
  ------------ ---------------------- ------------ ------------ ------------ ------------- -------------- ----------------
  AMP                                                                                                     
   Mean ± SD   5.0 ± 0.2              11.1 ± 0.1   23.9 ± 2.3   45.6 ± 0.4   90.7 ± 6.6    516.8 ± 4.9    1000.7 ± 1.3
   %RSD        3.5                    0.8          9.6          0.9          7.3           0.9            0.1
   %Bias       −0.5                   10.6         −4.2         −8.8         −9.3          3.4            0.1
  4-MA                                                                                                    
   Mean ± SD   5.2 ± 0.1              10.4 ± 0.6   25.0 ± 1.5   50.9 ± 1.6   95.9 ± 8.4    526.9 ± 31.4   1062.9 ± 4.7
   %RSD        1.5                    5.6          5.9          3.1          8.8           6.0            0.4
   %Bias       3.1                    4.1          0.2          1.7          −4.1          5.4            6.3
  MA                                                                                                      
   Mean ± SD   5.6 ± 0.1              11.0 ± 0.3   23.4 ± 1.9   44.0 ± 0.8   88.9 ± 0.7    443.0 ± 5.6    1043.7 ± 49.0
   %RSD        1.9                    3.1          8.1          1.9          0.8           1.3            4.7
  MDA                                                                                                     
   Mean ± SD   4.7 ± 0.2              9.1 ± 0.1    24.8 ± 1.7   45.1 ± 2.6   93.8 ± 7.4    480.6 ± 21.7   1047.3 ± 25.5
   %RSD        4.8                    1.2          7.0          5.8          7.9           4.5            2.4
   %Bias       −5.8                   −9.3         −0.9         −9.9         −6.2          −3.9           4.7
  MDMA                                                                                                    
   Mean ± SD   ---                    10.4 ± 0.8   26.5 ± 0.7   47.9 ± 4.2   89.0 ± 6.0    480.3 ± 19.3   1075.0 ± 8.9
   %RSD                               7.5          2.6          8.7          6.7           4.0            0.8
   %Bias                              4.1          6.0          −4.2         −11.0         −3.9           7.5
  MDEA                                                                                                    
   Mean ± SD   4.5 ± 0.1              9.1 ± 0.1    24.2 ± 1.2   50.7 ± 3.4   106.2 ± 7.4   478.3 ± 17.4   1051.7 ± 142.2
   %RSD        3.0                    1.1          4.9          6.7          6.9           3.6            13.5
   %Bias       −10.2                  −9.5         −3.0         1.4          6.2           −4.3           5.2
  EPH                                                                                                     
   Mean ± SD   5.1 ± 0.2              8.9 ± 0.2    26.0 ± 1.3   46.1 ± 2.8   99.7 ± 13.4   523.1 ± 18.4   1067.5 ± 60.4
   %RSD        3.5                    2.5          5.1          6.1          13.5          3.5            5.7
   %Bias       2.1                    −10.6        4.2          −7.8         −0.3          4.6            6.8
  CAT                                                                                                     
   Mean ± SD   4.9 ± 0.2              10.2 ± 0.6   23.7 ± 1.8   54.6 ± 2.7   111.3 ± 1.0   466.0 ± 39.0   981.8 ± 38.4
   %RSD        3.7                    5.9          7.8          4.9          0.9           8.4            3.9
   %Bias       −1.2                   2.3          −5.2         9.2          11.3          −6.8           −1.8
  MC                                                                                                      
   Mean ± SD   4.6 ± 0.4              10.0 ± 0.2   23.7 ± 1.8   51.8 ± 2.1   94.3 ± 8.8    488.2 ± 48.3   1077.0 ± 48.3
   %RSD        8.3                    2.2          7.7          4.1          9.4           9.9            4.5
   %Bias       −7.2                   −0.4         −5.2         3.5          −5.7          −2.4           7.7
  MEP                                                                                                     
   Mean ± SD   5.2 ± 0.1              11.0 ± 0.1   25.9 ± 1.4   47.6 ± 1.9   106.4 ± 8.0   500.5 ± 16.3   1041.3 ± 80.9
   %RSD        2.3                    0.6          5.6          4.0          7.5           3.3            7.8
   %Bias       3.3                    10.1         3.4          −4.9         6.4           0.1            4.1

Abbreviations: AMP, amphetamine; CAT, cathinone; EPH, ephedrine; 4-MA, 4-methylamphetamine; MA, methamphetamine; MC, methcathinone; MDA, 3,4-methylenedioxyamphetamine; MDEA, 3,4-methylenedioxy-*N*-ethylamphetamine; MDMA, 3,4-methylenedioxymethamphetamine; MEP, mephedrone; RSD, relative standard deviation.

A blank sample was analyzed after the highest point of the calibration curve and showed no peaks for the target analytes that the method is free from carryover.

The LOQ was measured in SIM mode using blank oral fluid fortified with all analytes at concentrations of 1, 2.5, 5, and 10 ng/mL. The S/N ratio was calculated from triplicate measurements. The lowest concentration at which the S/N ratio was equal or greater than 10 was considered as the LOQ. [Table 5](#table5-1177390117727533){ref-type="table"} presents the LOQ for all analytes using different derivatization methods. Selected ion monitoring chromatograms for the analysis of blank oral fluid and fortified sample at LOQ for all analytes are shown in [Figures 4](#fig4-1177390117727533){ref-type="fig"} to [6](#fig6-1177390117727533){ref-type="fig"}. Based on S/N, the best result was given by PFPA. Moreover, use PFPA as derivatizing reagent allows for very low values of the LOQs (2.5 and 5 ng/mL) for some amphetamines and cathinones compared with the method reported by Mohamed et al^[@bibr29-1177390117727533]^ and Rohrich et al.^[@bibr33-1177390117727533]^ which has LOQs of 20 and 9.8 to 20.2 ng/mL, respectively.

![Total ion chromatograms for the gas chromatography-mass spectrometry analysis of HFA derivatives of amphetamines and cathinones at (A) limit of quantification and (B) blank oral fluid. AMP indicates amphetamine; CAT, cathinone; EPH, ephedrine; 4-MA, 4-methylamphetamine; MA, methamphetamine; MC, methcathinone; MDA, 3,4-methylenedioxyamphetamine; MDEA, 3,4-methylenedioxy-*N*-ethylamphetamine; MDMA, 3,4-methylenedioxymethamphetamine; MEP, mephedrone.](10.1177_1177390117727533-fig4){#fig4-1177390117727533}

![Total ion chromatograms for the gas chromatography-mass spectrometry analysis of PFP derivatives of amphetamines and cathinones at (A) limit of quantification and (B) blank oral fluid. AMP indicates amphetamine; CAT, cathinone; EPH, ephedrine; 4-MA, 4-methylamphetamine; MA, methamphetamine; MC, methcathinone; MDA, 3,4-methylenedioxyamphetamine; MDEA, 3,4-methylenedioxy-*N*-ethylamphetamine; MDMA, 3,4-methylenedioxymethamphetamine; MEP, mephedrone.](10.1177_1177390117727533-fig5){#fig5-1177390117727533}

![Total ion chromatograms for the gas chromatography-mass spectrometry analysis of TFA derivatives of amphetamines and cathinones at (A) limit of quantification and (B) blank oral fluid. AMP indicates amphetamine; CAT, cathinone; EPH, ephedrine; 4-MA, 4-methylamphetamine; MA, methamphetamine; MC, methcathinone; MDA, 3,4-methylenedioxyamphetamine; MDEA, 3,4-methylenedioxy-*N*-ethylamphetamine; MDMA, 3,4-methylenedioxymethamphetamine; MEP, mephedrone.](10.1177_1177390117727533-fig6){#fig6-1177390117727533}

###### 

LOQ for HFA, PFP, and TFA derivatives of the target amphetamines and cathinones.

![](10.1177_1177390117727533-table5)

  Analyst   LOQ, ng/mL         
  --------- ------------ ----- -----
  AMP       10           2.5   2.5
  4-MA      2.5          2.5   2.5
  MA        2.5          2.5   2.5
  MDA       10           2.5   2.5
  MDMA      5            2.5   10
  MDEA      2.5          2.5   5
  CAT       2.5          2.5   5
  MC        2.5          2.5   5
  MEP       2.5          5     5
  EPH       2.5          2.5   2.5

Abbreviations: AMP, amphetamine; CAT, cathinone; EPH, ephedrine; HFBA, heptafluorobutyric anhydride; LOQ, limit of quantification; 4-MA, 4-methylamphetamine; MA, methamphetamine; MC, methcathinone; MDA, 3,4-methylenedioxyamphetamine; MDEA, 3,4-methylenedioxy-*N*-ethylamphetamine; MDMA, 3,4-methylenedioxymethamphetamine; MEP, mephedrone; PFPA, pentafluoropropionic anhydride; TFAA, trifluoroacetic anhydride.

No co-eluting peaks were observed except CAT, and 4-MA could not be separated effectively from EPH if they were derivatized with HFBA or TFAA. However, they have different fragment ions and can be distinguished from each other.

Conclusions {#section10-1177390117727533}
===========

Three acylation reagents, HFBA, PFPA, and TFAA, have been compared with use as derivatizing agents for the analysis of 10 amphetamines and cathinones in oral fluid by GC-MS. The 3 methods have suitable linearity, sensitivity, accuracy, and precision. Based on LOQ, PFPA is proved to be the best for derivatization of AMP, MA, 4-MA, MDA, MDMA, MDEA, CAT, MC, MEP, and EPH after liquid-liquid extraction from the oral fluid samples.
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